SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel's stock is surging amid reports of potential investments and partnerships with major players like Apple and TSMC, building on momentum from a recent deal with Nvidia. The community is buzzing about the possibilities of these collaborations, viewing them as a sign of a significant turnaround for the chipmaker. With government backing and strategic moves underway, investors are closely watching Intel's next steps in the evolving semiconductor landscape.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies, viewing the current dip as a buying opportunity before the next leg up. Active community members emphasize the project's ongoing developments, listings on multiple exchanges, and upcoming utilities, highlighting the development team's transparency and commitment. A buy contest is currently underway to push the price to the next milestone.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is trending as discussions highlight its potential to be the next PEPE, a popular meme coin, particularly within the Solana ecosystem. Community members are enthusiastic about its availability on Phantom Wallet and are closely watching its chart for bullish signals, anticipating a significant breakout.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Despite a recently announced hosting deal backed by Google, Cipher Mining is trending downwards, leading to discussions about dilution from a convertible note offering. The community is debating whether this dip is a buying opportunity, given the company's move into AI data centers and long-term growth potential, or a sign of market overvaluation. Some investors believe the long-term AI prospects and Google's involvement outweigh short-term concerns.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow With Knife ($CAW.X) is trending as the community highlights its multichain functionality across Solana, BSC, Cronos, and Ethereum, with a built-in burn mechanism. Community members are emphasizing its organic growth, strong community, and the deflationary nature of the token. Bullish sentiment is high as some users encourage buying the dip.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive ($DRV.X) is trending amid news of a potential collaboration with Synthetix to develop derivatives on the Ethereum network. The crypto community is actively discussing the possible implications of this partnership and anticipating future developments. Mentions of other cryptos, such as Bitcoin and Ethereum, suggest a broader interest in the derivatives space.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE.X is trending as the community rallies around the meme coin, expressing strong bullish sentiment and anticipating potential listings on major exchanges. The coin's association with the popular 'Rage Guy' meme and comparisons to other meme coins like TROLL are fueling discussions. Investors are actively encouraging community participation and further 'RAGING' to drive the coin's visibility.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending due to FDA approval for its oral acromegaly drug, PALSONIFY, sparking excitement among traders who anticipate a significant price movement. The community is focused on the potential for a short squeeze, given the high institutional ownership and short interest. Trading was halted following the news, adding to the speculation and anticipation.

Skywater Technology, Inc. is a holding company. It engages in the provision of semiconductor development, manufacturing services, and packaging services. The company was founded on October 3, 2016 and is headquartered in Bloomington, MN.

SkyWater Technology Inc

SkyWater Technology ($SKYT) is trending as discussions revolve around its potential in the semiconductor and quantum computing sectors, with community members highlighting upcoming revenue growth and government support. Some see catalysts related to quantum partnerships and domestic supply chain deals, while others discuss institutional ownership and technical analysis. Despite positive sentiment, concerns remain regarding potential government shutdowns and management decisions.

CarMax, Inc. is a holding company, which engages in the retail of used vehicles and wholesale of vehicle auction operators. It operates through the CarMax Sales Operations and CarMax Auto Finance (CAF) segments. The CarMax Sales Operations segment consists of all aspects of its auto merchandising and service operations. The CAF segment pertains to its finance operation, which offers vehicle financing services to customers buying retail vehicles. The company was founded by Richard L. Sharp and William Austin Ligon in 1993 and is headquartered in Richmond, VA.

Carmax Inc

CarMax ($KMX) is trending due to disappointing Q2 results, including a slump in car sales and rising loan loss provisions, leading to a breach of its 52-week low. The community is discussing whether the stock is now a bargain or if it signals broader issues in the auto industry, especially compared to competitors like Carvana. Some investors see the dip as an overreaction and buying opportunity, while others worry about debt and economic headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acadia Pharmaceuticals Inc. (ACAD) announced on Tuesday that its late-stage intranasal Carbetocin trial in Prader-Willi syndrome (PWS) patients did not achieve a statistically significant improvement in hyperphagia.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-phase-3-compass-pws-trial">study</a> enrolled 175 children and adults aged five to 30 years with PWS, a rare genetic disorder characterized by an insatiable hunger or hyperphagia and a constant need for food, leading to obesity. However, intranasal Carbetocin did not demonstrate a statistically significant improvement over placebo to week 12 on the Hyperphagia Questionnaire for Clinical Trials, the company said.The firm noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials, with a low rate of adverse events.Shares of the company tumbled 11% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACAD">ACAD stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Acadia’s Head of Research and Development, Elizabeth HZ Thompson, said that the company is “disappointed” by these findings. “We are committed to sharing a summary of the data in the future to ensure learning for the PWS community; however, given these results, we do not intend to investigate intranasal carbetocin any further,” Thompson added.CEO Catherine Owen Adams highlighted that the firm’s approved products are projected to generate over $1 billion in net sales in 2025 despite the disappointment with the trial. The company’s drugs for the treatment of Rett syndrome and for treating hallucinations and delusions associated with Parkinson’s disease psychosis are approved by the U.S. Food and Drug Administration.“Looking ahead, we anticipate seven Phase 2 or 3 study starts through 2026 and four data readouts by the end of 2027,” the CEO added.ACAD stock is up 29% this year and approximately 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-mp-materials-stock-rising-today/chD1R9FR330">Why Is MP Materials Stock Rising Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Acadia Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study 

The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.

Equity

The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.


Emergent BioSolutions Inc. (EBS) on Friday said that it has secured new purchase orders from an international government partner for a multiproduct supply agreement.The agreement is valued at $29 million, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-29-million-mcm-product-orders">said</a>. The order encompasses several product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism. The company said that this is the second procurement made by the same government this year.Shares of the company jumped 3% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/EBS">EBS stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_11_37_08_AM_png_46c276596d.webp" alt="EBS's Sentiment Meter and Message Volume as of 11:37 a.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>EBS's Sentiment Meter and Message Volume as of 11:37 a.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock is “significantly undervalued,” while indicating that they see more than 100% upside.<stembedurl>https://stocktwits.com/NRG8/message/629302236</stembedurl>Another user expects the stock to hit $10 next week.<stembedurl>https://stocktwits.com/shoagh12/message/629291934</stembedurl>Emergent said it will receive about $26 million in 2025 under the agreement. This is in addition to more than $100 million in sales already generated for the company’s MCM portfolio outside the U.S. so far this year, it said.“Together with demand from the U.S. government, these international procurements reinforce the potential for our growth trajectory as part of Emergent’s multi-year transformation plan and highlights the strength of Emergent’s global footprint,” CEO Joe Papa said. The CEO also added that the company continues to see countries elevating their investment in defense preparedness.Emergent delivers solutions for health threats like Smallpox, Mpox, Botulism, Ebola, Anthrax, and Opioid overdose emergencies.Earlier this week, the company also announced that it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply Tembexa oral suspension. At the start of the month, the company also announced that a contract modification had been executed for $56 million to supply ACAM2000, a live vaccinia virus vaccine approved by the FDA for use in preventing Smallpox and Mpox in individuals at high risk of infection, to the U.S. government.EBS stock is down 14% this year but up approximately 17% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-likely-preparing-22to24-per-share-bid-for-warner-bros-discovery/chD34ulR3Ta">Paramount Skydance Likely Preparing $22 To $24 Per Share Bid For Warner Bros. Discovery: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the Emergent BioSolutions logo of an US biopharmaceutical company is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’

The order encompasses multiple product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism.

RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite

Telsey Advisory Group stated that if an additional sector tariff on furniture is imposed, RH has the highest exposure within the home furnishings coverage group due to a high percentage of sales from furniture and limited sourcing in the U.S.

Maze Therapeutics, Inc. (MAZE) on Thursday announced that it has entered into a securities purchase agreement for the private placement of its securities for gross proceeds of about $150 million. Shares of the company soared 56% in the pre-market session at the time of writing.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-announces-oversubscribed-1500-million-private">private placement</a> involves the sale of over four million shares of common stock at $16.25 &nbsp;apiece, implying a premium of over 1% from the stock’s closing price on Wednesday. The placement is expected to close on September 12, the company said, while adding that both new and existing investors will participate.The firm said that the private placement includes participation from Frazier Life Sciences, Deep Track Capital, Driehaus Capital Management, Janus Henderson Investors, Logos Capital, TCGX, and Venrock Healthcare Capital Partners, as well as other healthcare-dedicated funds.The South San Francisco-based biopharmaceutical company is developing medicines for patients with kidney and metabolic diseases. It stated that it expects to utilize the proceeds from the placement to advance the development of MZE829 in patients with APOL1-mediated kidney disease, initiate mid-stage clinical trials of MZE782 in both phenylketonuria (PKU) and chronic kidney disease (CKD), and continue progress on its research and discovery programs. The company also intends to use the funds for working capital and other general corporate purposes.Last month, the company said that it ended June with cash and cash equivalents of $264.5 million, which it expects will fund operations into the second half of 2027.Separately, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-announces-positive-first-human-results-phase-1">also</a> announced positive clinical results from an early-stage study of MZE782, including “an excellent safety profile, robust target engagement and compelling pharmacodynamic effects.” The firm stated that the study data in 112 healthy volunteers exceeded expectations, enabling mid-stage advancement in the treatment of both PKU and CKD in 2026.Maze went public in January. The stock is up by 0.4% since its listing.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-in-consolidation-mike-novogratz-sees-solana-ethereum-taking-spotlight/chwN1oPRdvg">‘Bitcoin in Consolidation’ – Galaxy’s Mike Novogratz Reportedly Sees Solana, Ethereum Taking Spotlight For Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Maze Therapeutics Stock Just Shot Up 56% Pre-Market Today – Here’s What Happened

The company announced a private placement for over four million shares of common stock at $16.25 apiece, representing a premium of over 1% from the stock’s closing price on Wednesday.

Ionis Pharmaceuticals, Inc. (IONS) announced on Tuesday that its medicine, Olezarsen, reduced triglycerides and acute pancreatitis events in late-stage trials evaluating the drug in individuals with severe hypertriglyceridemia.Severe hypertriglyceridemia (sHTG) is defined by severely high triglycerides reaching into the thousands. It is characterized by an increased risk of acute pancreatitis and other morbidities. According to Ionis, approximately three million people are living with sHTG in the U.S., including more than one million who are considered high risk.In two <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ionis.com/news-releases/news-release-details/olezarsen-significantly-reduces-triglycerides-and-acute">studies</a>, Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months, as well as a highly statistically significant 85% reduction in acute pancreatitis events, with favorable safety and tolerability profiles. The two trials cumulatively enrolled nearly 1,100 patients who were required to be on standard-of-care lipid-lowering therapy throughout the treatment period.<a href="https://stocktwits.com/symbol/IONS">IONS stock</a> rocketed by 34% by Tuesday afternoon, reaching its February 2021 highs. On Stocktwits, retail sentiment around IONS jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_2_02_09_PM_png_166853294f.webp" alt="IONS's Sentiment Meter and Message Volume as of 2:02 p.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="624" height="59"><figcaption>IONS's Sentiment Meter and Message Volume as of 2:02 p.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the company’s future.<stembedurl>https://stocktwits.com/Mookins/message/627214651</stembedurl>Sam Tsimikas, senior vice president of global cardiovascular development at Ionis, termed the data “groundbreaking” and noted that the data reinforce the company’s confidence that the medicine has the potential to change how sHTG is treated. According to the firm, current standard of care therapies for sHTG and lifestyle modifications do not sufficiently or consistently lower triglyceride levels or reduce the risks of sHTG in all patients.Ionis plans to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration for approval of Olezarsen in sHTG by the end of the year. The drug is already approved in the U.S. as Tryngolza as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia (FCS).Several analysts hiked their price target on the stock following the news:<ul style="list-style-type:square;"><li>H.C. Wainwright raised its price target to $95 from $70 while keeping a ‘Buy’ rating on the shares. The firm also hiked its forecast for global Olezarsen sales up to $4.2 billion from $3.2 billion.</li><li>Jefferies raised its price target to $96 from $83 and kept a ‘Buy’ rating on the shares. The firm increased its estimate of Olezarsen's peak sales to about $2.5 billion from $1.5 billion due to higher assumed penetration in sHTG.&nbsp;</li><li>Barclays raised its target to $78 from $58, while keeping an ‘Overweight’ rating on the shares.</li><li>Morgan Stanley raised its price target to $71 from $62 and kept an ‘Overweight’ rating on the shares.</li></ul>IONS' stock is up 64% this year and approximately 21% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nio-expects-sales-bump-for-remainder-of-year-after-new-models-bring-strong-demand/chv6z3WRdFg">Nio Expects Sales Bump For Remainder Of Year After New Models Bring In Strong Demand: Retail Sees Stock Hitting At Least $10 By Year-End</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ionis Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies 

In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months. 

American Century ETF Trust - Avantis Responsible U.S. Equity ETF

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

AVSU
American Century ETF Trust - Avantis Responsible U.S. Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest AVSU News

AVSU American Century ETF Trust - Avantis Responsible U.S. Equity ETF